Alopecia or hair loss can be a common but distressing condition. Our company has developed and patented a new treatment using a topical spray application of zinc-thymulin that is a combination of two natural compounds. Our results have been published in January 2017 in the international peer reviewed journal Hair Therapy and Transplantation. The treatment works in males and females across a wide age range.
FAQs (answers based on our research publication)
  • ​​What is the active compound: it is called zinc-thymulin and is a combination of a two naturally occurring compounds, zinc an essential element and thymulin that is a polypeptide composed of amino acids. The preservatives are benzoic acid, potassium sorbate and sodium benzoate and are widely used in the food and cosmetic industry. Buffering compounds to achieve the ideal hair pH 5.4 are citric acid and sodium carbonate.
  • Is there proof it works: yes, the trial results were published on January 26th, 2017 in the international peer reviewed medical scientific journal of Hair Therapy and Transplantation.
  • How does it work: zinc and thymulin combine together to stimulate the anagen hair growth phase. The compound is in a liquid water based solution that is sprayed to the scalp. The solution is odourless, colorless and does not react with hair dye in the subjects who used it in the trial.
  • Is it safe: yes, the research showed no scalp irritation or any side effects.
  • Who can use it: men and women suffering hair loss from androgenetic alopecia. The zinc-thymulin compound also induces melanin in the hair follicle and reverses greying hair.
  • Can it work in all people: this is a treatment based on our published research where hair growth results can vary on an individual basis. Your expectations must be realistic and hair growth cannot be guaranteed.
  • Can it work with minoxidil, finasteride and hair transplants: yes
  • Who should not use it: people who have a medical condition of the scalp such as inflammation, infection or lesions must seek professional medical advice
  • How much does it cost: $2400 (incl. GST) per year. There is an initial consultation fee of $480. 
  • Where can I buy it: currently it is only available from our Sydney clinic and after a consultation with Dr Vickers or his clinical representative staff. It is anticipated that doctors in other Sydney and interstate clinics will be trained in the future. Our company has filed an international patent on this product.
  • Will there be more research in this product: yes, our clinic has a strong emphasis on continued research such as a randomised controlled trial.
  • Are photos taken: yes, if you agree to proceed with treatment then baseline photos are taken by our computer imaging assistant. These include macroscopic, microscopic, spectroscopic and thermographic images and copies of images can be emailed to you on request.
  • Rosebery Medical Centre has a counsellor with expertise in stress management: hair loss can be caused by stress and treating stress may be necessary if it is present and part of your individual treatment plan. For example, these are questions where psychological treatment may be needed: 1) has hair loss increased your levels of stress about appearance, self-esteem, relationships and engaging in social activities, 2) has there been any significant emotional or physical trauma just prior to hair loss, 3) is there any previous or current mental health issues such as anxiety, depression, post-traumatic stress.

ER Vickers, Hair Therapy and Transplantation, 2017. Summary Abstract. Open access full text doi:10.4172/2167-0951.1000147

Objective: To assess the safety and efficacy of the metallopeptide zinc-thymulin (ZT) for treating androgenetic alopecia (AGA). Previous in vitro studies have described that different thymic peptides can both increase and decrease anagen (thymulin and thymosin beta-4, respectively). Zinc is an essential element and serum zinc deficiency can cause hair loss. Methods: Eighteen consecutive adult subjects were recruited, 17 males and 1 female, age range 35-90 years (mean 55.4, SD 13.3) with a diagnosis of AGA, Norwood classification 2-7, and hair loss duration range of 3-40 years (mean 15.8, SD 9.6). The trial duration for each subject ranged from 4-10 months. The test compound ZT was synthesized by standard Fmoc peptide protocols and administered in water based topical spray to the scalp. Baseline and after treatment images for hair growth were graded by two blinded assessors using two validated scales: 1. numerical visual analog scale (VAS) for global assessment 2. hair growth index (HGI) of images under higher magnification for percentage changes of vellus, intermediate and terminal hair. Results: ZT demonstrated no adverse systemic effects or local side effects of redness or scalp irritation in any subject over a total of 3,300 treatment days. Three subjects who were concurrently using minoxidil (N=2) and minoxidil / finasteride (N=1) did not report any drug interaction with ZT. VAS hair assessment improvement was significant in subjects who completed 6 months of treatment (P=0.045, t-test). HGI assessment showed a significant increase in the number of newly observed intermediate hairs in previous “absent hair” regions (P<0.0001) with an average increase of vellus type (32%) and intermediate type (23%) hairs at 6 months. Melanogenesis was observed in several subjects. Conclusion: Topical applications of ZT demonstrated safety and established efficacy for initiating and maintaining anagen to treat male pattern baldness when applied for>6 months.